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Abstract 
 
Introduction  
The range and magnitude of potential benefits and harms of antihypertensive treatment in people with 
dementia has not been previously established. 
Method 
A scoping review to identify potential domains of benefits and harms of antihypertensive therapy in 
people with dementia was undertaken. Systematic reviews of these domains were undertaken to 
examine the magnitude of the benefits or harms. 
Results 
Potential outcome domains identified in the 155 papers in the scoping review were cardio-vascular 
events, falls, fractures and syncope, depression, orthostatic hypotension, behavioural disturbances, 
polypharmacy risks, kidney problems, sleep problems, interactions with cholinesterase inhibitors and 
pain. The systematic reviews across these domains identified relatively few studies done in people 
with dementia, and no convincing evidence of safety, benefit or harm across any of them. 
Discussion 
There is no justification for materially different guidance for the treatment of hypertension in people 
with dementia, but sufficient evidence to warrant particular caution and further research into treatment 
in this group of patients.      
     
Introduction 
The WHO 2012 report “Dementia: a public health priority” estimated that there are 35.6 million people 
with dementia living at present worldwide
1
. About half of people over 50 years of age have 
hypertension
2
. While the protective effects of antihypertensive treatment against cardiovascular 
events have been established in numerous clinical trials for different age groups
3-4
 including the very 
old
5
, people with dementia have been consistently excluded from these studies. The favourable 
benefit to risk ratio seen in studies of hypertension treatment in fit older people might not apply if 
people with dementia are at a higher risk from the side effects of anti-hypertensive treatment than 
people with normal cognition (for example through falls or other adverse drug effects), and if they are 
less likely to be recognised or reported than in those with normal cognition. Therefore management of 
hypertension in people with dementia may need to be different from in those with normal cognition
6
. 
However, current guidelines for the treatment of hypertension do not provide specific advice for 
people with dementia. 
 
There have been no reviews to comprehensively examine studies investigating the range of outcomes 
(including harmful effects) of antihypertensive treatment in people with dementia. Such work is 
important to clarify whether there is a case for altered guidance for the management of hypertension 
in people with dementia.  
 
Methods 
A two stage process was undertaken. In the first stage, a scoping review
7
 was undertaken to identify 
the range of outcomes of antihypertensive treatment in people with dementia. In the second stage, 
systematic reviews were undertaken for each of the main areas of harmful or adverse outcomes 
identified in the first stage.  
 
Stage 1: scoping review 
 
Protocol 
The scoping review was based on a pre-defined protocol to search and identify relevant research 
articles. 
 
Eligibility 
Inclusion: All articles reporting original research regarding the treatment of hypertension in people 
with dementia were included. No publication date limit was applied 
Exclusion: All studies investigating hypertension as a risk factor for dementia; effects on carers; 
specific non-dementia diseases (e.g. cancer) and rarer forms of dementia (Korsakoff’s syndrome, 
dementia due to HIV, normal pressure hydrocephalus, CADASIL); animal studies and non-English 
language articles. As effects of antihypertensive drugs on the progression of dementia have been 
reviewed elsewhere
8-9
, they were excluded from the literature analysis. 
 
Information sources 
Pubmed, Embase, Web of Science and the Cochrane library databases were searched.  
 
Search  
The search for articles took place from July 2012 and was updated in February 2013. Searches were 
limited to English language human research articles. Search terms included combinations of 
‘hypertension’, ‘antihypertensive drug’, ‘antihypertensive treatment’ or ‘blood pressure’ in combination 
with ‘dementia’ or ‘Alzheimer’s disease’ 
 
Selection 
Duplicates were removed, titles and abstracts were examined by one person (Vv/dW) and inclusion 
and exclusion criteria applied. Full text versions of the remaining papers were obtained and assessed 
again based on inclusion and exclusion criteria. The remaining relevant articles were used to identify 
the range of outcomes examined in scientific articles.  
 
Data collection 
Main outcome variables were recorded and categorized into topics.   
 
Analysis 
The number of papers examining each outcome was tabulated.  
 
Stage 2 systematic reviews 
 
Protocol 
The systematic reviews were based on a pre-defined protocol to search and identify relevant research 
papers. 
 
Eligibility 
Inclusion: All articles reporting original research regarding antihypertensive treatment in people with 
dementia and the topic identified in stage 1 were included. No publication date limit was applied. 
Exclusion: As in stage 1. Studies which did not include antihypertensive treatment in any form in the 
analysis (as composite variable or individual medication classes) were also excluded.  
 
Information sources 
Pubmed, Embase, Web of Science and the Cochrane library databases were searched.  
 
Search  
Articles were searched until June 2013 publication dates. Searches were limited to English language 
and, where possible, human research articles. Search terms for stage 2 included ‘antihypertensive’ or 
antihypertensive drug classes (‘diuretics’, ‘beta blockers’, ‘calcium channel blockers’, ‘angiotensin 
receptor blockers’ and ‘ACE inhibitors’) in combination with ‘dementia’ or ‘Alzheimer’s disease’ and 
the topics identified in stage 1 (see flow diagram 1). 
 
Selection 
Duplicates were removed, titles and abstracts were examined by one person (VvdW) and inclusion 
and exclusion criteria applied. Full text versions of the remaining papers were obtained and assessed 
based on inclusion and exclusion criteria. The remaining relevant articles were included and the 
number of papers examining each topic was recorded.  
 
Data collection 
Methods and results were extracted to record purpose of the study, design, sample size, main 
measurements and results of each study.  
 
Analysis 
Method sections of papers were examined to determine level of evidence. Results were compared 
and analysed regarding the effect of antihypertensive treatment on the topic in question.  
 
Results 
Stage 1 - Scoping review 
Figure 1 shows that 155 papers entered this review.  
Figure 1 Scoping review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ten main outcome themes of effects of antihypertensive treatment in people with dementia emerged 
from the 155 papers in the scoping review (flow diagram 1); cardio-vascular events, falls, fractures 
and syncope, depression, hypotension, behavioural disturbances, polypharmacy, kidney problems, 
sleep problems, cholinesterase inhibitors and pain. The articles identified in the last stage of the 
scoping review were also included into the stage 2 analysis.  
 
Stage 2 – Systematic reviews  
7715 articles identified through 
Pubmed, Embase, Web of Science 
and the Cochrane library 
2333 articles after exclusion 
criteria were applied to title 
155 articles remained in the scoping review: 
 Cardio-vascular events (30) 
 Falls, fractures, syncope (26) 
 Depression (20) 
 Hypotension (20) 
 Behavioural disturbances (15) 
 Polypharmacy (12) 
 Kidneys (15)  
 Sleep (8)  
 Cholinesterase Inhibitors (5)  
 Pain (4) 
 
 
5382 articles eliminated based on 
exclusion criteria applied to titles 
1892 articles eliminated based on 
exclusion criteria applied to 
abstract 
441 articles after exclusion 
criteria were applied to abstracts; 
full text versions were examined 
286 articles eliminated based on 
exclusion criteria  
Table 1 shows a summary of the findings of the searches undertaken in the systematic reviews of the 
topics identified in the scoping review. 
Table 1 Search terms ‘dementia’ or ‘Alzheimer’s’ in combination with antihypertensive, diuretics, beta 
blockers, calcium channel blockers, angiotensin receptor blockers or ACE inhibitors 
Search terms  No. of articles 
for which full 
texts were 
obtained  
No. of articles 
investigating effects of 
antihypertensive 
treatment in people 
with dementia 
Stroke, cardiovascular 107 5 
Falls, fractures, syncope 58 4 
Behavioural problems, 
aggression, agitation, apathy 
13 5 
Depression 18 2 
Sleep, insomnia, pain, 
kidney, renal problems, 
incontinence 
39 2 
Eyes, retinal, glaucoma 15 0 
Cholinesterase inhibitors 15 4 
Polypharmacy 23 2 
Hypotension 20 2 
 
  
1 Cardio- and cerebrovascular events 
In total, four studies examined the effects of antihypertensive medication on cardio- and 
cerebrovascular events in people with dementia (see table 2), with antihypertensives either as main 
independent variable (three studies) or as control variable (one study).  
No randomized controlled placebo trials have been conducted in this area. In people with dementia, 
two randomized controlled trials investigated the effects of calcium channel blockers (CCBs) in an 
intention-to-treat, a efficacy and a safety analysis
10-12
. For both trials, main outcome was cognition but 
the safety analysis included cardio- and cerebrovascular events, which were reported as adverse 
events. The studies compared a control group against a treatment group using CCBs. Both groups 
were allowed to continue with unspecified antihypertensive treatment as prescribed before the 
beginning of the study except alpha methyldopa. The results showed that the control group had 
significantly more adverse (cerebrovascular) events than the treatment group
11-12
. For cardiovascular 
events the trend was similar but reached significance in only one of the studies
12
. In a subgroup 
analysis of participants with sub-cortical vascular dementia
13
, no significant differences in these 
adverse events were found, although again the same trend was observed (fewer events in the 
treatment group). One study was a non-randomized six weeks open label trial including people with 
dementia into the safety of Nivladipine (CCB)
14
. There was no significant difference in adverse events, 
but this was a very short period of follow up. 
  
In addition, a prognostic cohort study including a large group of people diagnosed with dementia 
investigated the effects of angiotensin receptor blockers and ACE inhibitors on the risk of 
hospitalization and mortality while controlling for cerebro-and cardiovascular events
10
. The results 
showed that while there was no significant association between angiotensin receptor blockers and 
risk for hospitalisation or mortality, ACE inhibitors significantly increased the risk for mortality but not 
for hospitalisation. This association remained significant after controlling for coronary heart disease, 
stroke and congestive heart failure. 
 
Falls, fractures and syncope  
The risk of falls and fractures is higher in people with dementia compared to those without
15-17
. In 
addition, some antihypertensive treatments have been shown to increase the risk for falls and 
fractures in older people
18-19
. However, this review found no evidence from randomized controlled 
trials for the risk of falls due to antihypertensive medication in people with dementia. This review 
identified four prospective cohort studies, two of those investigating the association between falls risk 
and antihypertensive medication in people with dementia
20-22
, and a further two examining the 
association of falls risk with cardiovascular medication
23-24
 (Table 2). Cardiovascular medication 
included antihypertensive drugs as well as anticoagulants and antiplatelet agents.  
 
The findings showed conflicting results in people with dementia. Examining risk factors for falls in 
people with and without dementia, Eriksson et al.
20-21
 found that taking diuretics was a significant risk 
factor for falls for people with dementia in a univariate analysis, but this was non-significant when 
controlled for significant covariates, but taking more than four drugs was a significant risk factor for 
falling in people with dementia after controlling for significant covariates. Pellfolk et al.
22
 found no 
significant difference in the use of antihypertensive medication between fallers and non-fallers in 
people with dementia and therefore did not enter antihypertensive medication in their logistic 
regression analysis of independent risk factors of falls. However, Allan et al.
23
 reported that 
cardiovascular medication was a significant predictor of falls in an analysis of all types of dementia 
combined (Alzheimer's disease, vascular dementia, dementia with Lewy bodies and Parkinson's with 
dementia), as well as when stratified per dementia type. When significant and potentially modifiable 
predictors were entered into a multivariate analysis, which was stratified by dementia type, 
cardiovascular medication remained significantly associated with falls. Asada et al.
24
, on the other 
hand, found that cardiovascular medication was not a significant contributor to falls-related injuries in 
people with dementia. 
 
Behavioural problems 
Only the effects of beta (Propranolol/Pindolol) and alpha blockers (Prazosin) on behavioural 
symptoms in people with dementia have been investigated in randomised controlled trials (Table 2). 
All three trials had very small sample sizes (between 6 and 31 participants) but showed a significant 
beneficial effect of centrally active antihypertensive medication on behavioural problems. Herrmann et 
al.
25
 showed that verbal aggression was significantly reduced in people using beta-blockers, without a 
significant change in total aggression. Peskind, Tsuang and Bonner
26
 found no significant association 
between use of beta blockers and any specific behavioural subscale but a significant effect of beta 
blocker use on the total behavioural score. A small randomised controlled trial to assess the effect of 
alpha blockers on behaviour showed that non-significantly greater improvements in the treatment 
group than in the control group
27
. A case series study to assess the effect of beta blockers on 
behaviour in people with dementia
28
 indicated significant improvements for all behavioural measures 
(except for wandering, which improved on only one scale). Behavioural improvements after using beta 
blockers were also found in another case study including people with dementia
29
. Meta-analyses 
showed that beta blockers have relatively little effect on cerebro- and cardiovascular events and 
mortality compared to other antihypertensive drugs
30-31
, and are more likely to be discontinued
32
. 
Other antihypertensive treatments have not been investigated for their effect on behavioural 
problems.  
 
Depression  
Antihypertensive treatment, in particular the use of highly lipid-soluble beta blockers, has been 
associated with depression
33
. One randomised controlled trial and one cohort study investigated the 
relationship between antihypertensive treatment and depression in people with dementia. The 
randomised controlled trial investigated the effect of Nimodipine (CCB) on depression in patients with 
diagnosed dementia as well as those with mild to moderate cognitive decline on the Global 
Deterioration scale
34
. The treatment and control group were allowed to use other medication including 
antihypertensive treatment. Scores on the Hospital Anxiety and Depression scale improved 
significantly more in the treatment group than in the control group. In a large cohort study examining 
the prevalence of depression in people with dementia, Newman
35
 found that beta blocker use was not 
a significant covariate in the relationship between dementia and diagnosis of major depression. No 
other antihypertensive drugs were included in the analysis.  
 
Sleep problems, pain, kidney problems and incontinence 
Although these topics emerged during the first stage of this review, there were only a very few studies 
investigating the effect of antihypertensive medication in people with dementia (Table 2).  
Sleep problems are common in people with dementia
36-37
, and sleep disturbances, in particular 
obstructive sleep apnoea, have been shown to improve with antihypertensive treatment
38
. While there 
are no studies examining the effects of antihypertensive treatment on sleep quality, one prospective 
cohort study investigated the relationship between sleep disturbances and nocturnal reduction of 
blood pressure in people with dementia whilst controlling for antihypertensive treatment
39
. The results 
showed no significant difference in use of antihypertensive medication between dippers (hypertensive 
patients who experience a nocturnal reduction in blood pressure) and non-dippers (those who do not). 
Other sleep disturbances have not been investigated in people with dementia in relation to use of 
antihypertensive medication.  
Some antihypertensive drugs such as beta blockers, angiotensin receptor blockers and ACE inhibitors 
seem to have beneficial effects on pain in older people without dementia
40-41
. For people with 
dementia, however, the association between pain and antihypertensive treatment has not yet been 
investigated.   
The relationship between kidney problems and antihypertensive medication has not been assessed in 
people with dementia. One cohort study including geriatric emergency patients investigated the 
association. The results showed that antihypertensive drugs may contribute to an increased risk of a 
clinically relevant impairment of renal function
42
. However, although 56% of the participants were 
diagnosed with dementia and no separate analysis for this group was conducted.   
The effect of antihypertensive drugs on incontinence has been examined by Ruby et al.
43
 in a large 
cohort study of older people. They reported that use of alpha blockers was significantly associated 
with urinary incontinence. Ridgeway et al.
44
 investigated the relationship between incontinence and 
use of antihypertensive medication in a long-term care population with 79% being diagnosed with 
dementia. The results indicated that while dementia was significantly associated with urinary and 
faecal incontinence, antihypertensive medication was not individually related to incontinence. 
However, a sub-analysis including only people with dementia was not reported.  
 
Use of Cholinesterase inhibitors 
Cholinesterase inhibitors are commonly used in the mild to moderate stages of Alzheimer's disease. 
Several studies investigated the interaction effects between cholinesterase inhibitors and 
antihypertensive medication (Table 2) although the evidence is limited to cohort studies and 
population database studies, no randomised controlled trials have been conducted to assess these 
effects.  
The results of a prospective cohort study
45
 showed significant better cognition in those taking 
antihypertensive drugs compared to those not taking them. Other studies, however, demonstrated 
that the joint use of antihypertensive medication and cholinesterase inhibitors was associated with a 
significantly increased risk of serious adverse drug reactions. Grossberg et al.
46
 found no significant 
interaction between rivastigmine and antihypertensive medication as a group in their cohort study but 
when analysed separately, the use of diuretics and rivastigmine was related to a significantly higher 
rate of serious adverse events while centrally acting antihypertensives, ACE inhibitors and calcium 
channel blockers were not. Furthermore, the results of two database studies showed that use of 
antihypertensive treatment was significantly associated with serious adverse drug reactions in 
patients treated with cholinesterase inhibitors
47
 and beta blockers were among the most frequently 
encountered drugs involved in drug-drug interactions with cholinesterase inhibitors
48
. 
These studies indicate that the combination of cholinesterase inhibitors and antihypertensive 
medication might result in benefits (improvement of cognition) as well as harms (serious adverse drug 
reactions), which might depend on drug class.  
 
Polypharmacy and inappropriate medications 
All antihypertensive medications contribute to polypharmacy and its harmful effects
49
, but only two 
cohort studies investigated antihypertensive drug use in the context of polypharmacy in people with 
dementia (Table 2). A longitudinal cohort study compared drug use between people with and without 
dementia
50
, showing that people with dementia used significantly more loop diuretics than people 
without dementia, and significantly less beta blockers and calcium channel blockers. Inappropriate 
antihypertensive drug use (estimated daily dose in excess of assumed average maintenance dose 
per day of a drug used for its main indication in an adult) did not differ between people with and 
without dementia. Montastruc et al.
51
 investigated the use of potentially inappropriate medication in 
people with dementia in a cohort study, showing that 3.1% of people with mild to moderate 
Alzheimer's disease used inappropriate centrally acting antihypertensive medication and 2.9% used 
inappropriate short-acting calcium-channel inhibitors.  
 
Orthostatic hypotension 
Orthostatic hypotension is associated with poorer cognition
52-53
 and occurs significantly more often in 
people with dementia than without
54
. However, the role of antihypertensive medication in this context 
is unclear. Again, no randomised controlled trials have been conducted to examine the relationship 
between antihypertensive treatment and hypotension in people with dementia. The non-randomised 
open label trial, which looked at safety of Nivladipine for people with dementia
14
, found no significant 
difference between treatment and control group in the incidence of orthostatic hypotension.  
In a cross-sectional cohort study, Anderson et al.
54
 found that differences in incidence of orthostatic 
hypotension between people with Alzheimer's disease, Lewy Body dementia and without dementia 
were independent of the use of antihypertensive treatment. Mehrabian et al.
55
 confirmed these results 
in a cohort study including people with memory complaints including dementia when looking at use or 
no use of antihypertensive treatment (Table 2).  While worse cognitive function and number of 
different antihypertensives were significantly associated with orthostatic hypotension, it was not 
reported if the number of different antihypertensive drugs was significantly related to orthostatic 
hypotension for the dementia group separately.  
Table 2 Articles included in the analysis 
Area Author & 
year 
Research question Design Sample size Main measurements Results 
Cardio- and 
cerebro-
vascular 
events 
Kehoe, 
Davies & 
Martin 
(2013) 
[10] 
How do ACE-Is and 
ARBs affect the 
risk for 
hospitalization and 
mortality in people 
with dementia? 
Prognostic 
cohort study 
based on 
primary care 
database 
N=6290 (all with 
dementia diagnosis and 
using AHT) 
Health 
Death 
Hospitalisation 
ACE-Is: sig associated with 
mortality in patients with AD (HR 
1.19; CI* 1.07-1.33) and 
combined dementia group (HR 
1.20; CI 1.10-1.30) after 
adjustments but no association 
with hospitalization;  
ARBs: no significant associations 
Kennelly, & 
al. (2011) 
[14] 
Is nivladipine save 
and tolerable for 
people with AD? 
Non-
randomized 
open label 
trial (6 wks) 
Treatment group n=56; 
control group n=30 all 
used other AHTs as well 
Inappropriate 
reduction in BP 
AEs 
Falls (self report) 
Orthostatic 
symptoms  
No sig. effect on BP after 
adjustments; no change in OH in 
either group; no significant 
difference in reported AEs between 
groups but more AEs in treatment 
group 39.0% vs 23.3 in control 
group). 
Pantoni, 
Bianchi, & 
al. (2000) 
[11] 
Is nimodipine 
efficient in 
improving 
cognition and 
slowing 
deterioration as 
well as save for 
people with multi-
infarct dementia? 
Double blind 
RCT intention 
–to-treat (itt), 
safety and  
efficacy 
analyses 
Treatment n=128; 
control n=131; safety 
analysis n=259;  
itt n=251, efficacy 
n=209, all multi-infarct 
dementia, controls used 
other AHTs 
Functional rating 
scale 
ADL 
Rapid Disability 
Scale, CDR 
Clinical Global 
Impression 
Cognition 
AEs and SAEs 
AEs and SAEs analysis showed 
that only cerebro-vascular events 
were sig. more in placebo group 
(AE: 6 in treatment vs 17 in 
placebo group; SAE: 16 in 
treatment vs 22 in placebo group, 
Other results concerning cognition 
or functioning are all non 
significant. 
Pantoni, 
Rossi & al. 
(2000) 
[13] 
Is nimodipine 
efficient in 
improving 
cognition and 
slowing 
deterioration as 
well as save for 
people with 
subcortical 
vascular dementia? 
Sub analysis 
of double blind 
RCT; intention 
–to-treat (itt), 
safety and 
efficacy 
analyses 
Treatment n=45; control 
n=47; safety analysis 
n=92;  
itt n=87, efficacy n=77, 
all subcortical VaD, 
controls use other AHTs 
Functional rating 
scale 
ADL 
Rapid Disability 
Scale, CDR 
Clinical Global 
Impression 
cognition 
AEs and SAEs 
Due to low numbers, no statistical 
significance could be established 
but more controls than people in 
treatment group had SAEs and 
total AEs. More people in 
treatment group had BP values 
indicating hypotension  
Pantoni, & 
al. (2005) 
Is nimodipine 
efficient in 
Double blind 
RCT intention 
Treatment n=124 
(baseline)/94 (endpoint); 
Sandoz Clinical 
Assessment Geriatric 
Cognitive decline in some aspects 
less in treatment group; AEs and 
[12] improving 
cognition and 
slowing 
deterioration as 
well as save for 
people with 
subcortical 
vascular dementia? 
–to-treat (itt), 
safety and  
efficacy 
analyses 
control n=118 
(baseline)/55 (endpoint); 
safety analysis n=239;  
itt n=230, efficacy 
n=149, all subcortical 
VaD, controls use other 
AHTs 
Scale 
Global Deterioration 
Score 
Gait performance 
test 
Nurses Observation 
Scale 
Clinical Global 
Impression 
depression 
 
SAE reported sig. more in placebo 
than treatment group (AE: RR 
1.29, CI 1.03-1.61; SAE: RR 1.58, 
CI 1.03-2.42) in particular 
cardiovascular and 
cerebrovascular events – 9 in 
treatment group vs 28 in placebo 
group); no sig. effects blood 
pressure levels.  
Falls Allan & al. 
(2009) 
[23] 
What are the 
modifiable risk 
factors for falls in 
people with 
dementia?  
Prospective 
cohort study 
(12 mths) 
Total n=179,  
Controls n=39, AD n=38, 
VD n=32, DLB n=30, 
PDD n=40 
Medical history, 
CAMCOG, physical 
activity scale, BMI, 
mobility, PD rating 
scale, ADL, 
depression, 
behavioural 
symptoms, 
autonomic 
assessment (OH), 
falls 
Cardiovascular medication only: 
sig. predictor in univariate analysis 
for all dementia (HR 2.08; CI 
1.15-3.75) and when stratified per 
diagnosis (HR 1.91; CI 1.03-
3.54); Trend sig. in multivariate 
analysis when stratified by 
diagnosis (HR 1.98; CI 0.994-
3.96) 
Asada & al. 
(1996) 
[24] 
What are the 
predictors of fall-
related injuries in 
people with 
dementia? 
Prospective 
cohort study 
(12 mths) 
Total n = 184 
98 controls, 86 people 
with dementia 
Cognition, 
behavioural 
problems, ADL, 
medication, history 
of falls, visual & 
hearing acuity, falls 
Cardiovascular medication only: 
non significant contributor to falls-
related injuries (OR 0.9; CI 0.6-
1.5) 
Eriksson, & 
al., 2007 
[20] (incl. 
erratum 
[21]) 
What are the risk 
factors for falls in 
people with and 
without dementia? 
Prospective  
cohort study 
(6 mths) 
Total n = 186,  
83 without dementia;  
103 with dementia 
Cognition, vision, 
hearing, walking 
ability, ADL, 
medication, falls 
In Erratum: In people with 
dementia in univariate analysis, 
taking diuretics was a significant 
risk factor (IRR 1.86; CI 1.07-
3.23). Not significant in 
multivariate analysis. 
Pellfolk & 
Gustafsson 
(2009) 
[22] 
What are the risk 
factors for falls in 
people with 
dementia?  
Prospective 
study cohort 
(6 mths) 
Total n = 160 people 
with dementia; of those 
n= 64 fallers and n= 96 
non fallers 
Cognition, vision, 
hearing, ADL, 
behavioural and 
psychiatric 
symptoms, use of 
medication, falls 
No sig. difference in AHT (beta-
blockers, CCB, ACE inhibitors, 
diuretics) between fallers and non-
fallers. No effect sizes reported. 
Behavioural 
problems 
Herrmann 
& al. 
(2004) 
[25] 
What is the 
relation between 
aggression and BB 
use in AD patients? 
RCT (cross-
over design); 
total duration 
15 wks 
Total n = 11 Aggression 
(retrospective Overt 
Aggression Scale), 
MMSE, Depression,  
Sig. decrease in verbal aggression 
in treatment group but not in total 
aggression score; higher baseline 
aggression, higher MMSE and 
lower growth hormone response to 
clonidine challenge predicted 
improvement in aggression. No 
effect size reported. 
Peskind, 
Tsuang & 
Bonner 
(2005) 
[26] 
Does propranolol 
(BB) reduce 
disruptive 
behaviour?  
RCT (6wks) Total n= 31 with 
probable or possible AD; 
n=17 on BB, n=14 
placebo 
NPI change,  
Clinical Global 
Impression of 
Change  
Overall score of NPI but no 
individual sub-score sig. 
improved in treatment group 
compared to placebo group. 
However, within treatment 
group, results showed sig. 
reductions in agitation/ 
aggression scores and anxiety 
scores from baseline to follow-
up. No effect size reported. 
Shankle, 
Nielson, & 
Cotman, 
(1995) 
[28] 
Does low-dose 
propranolol (BB) 
reduce aggression 
and agitation in 
people with 
dementia? 
Case series, 
mean follow-
up 6 mths 
Total n = 12 Aggression (by 
proxy; caregiver 
rating, CMAI, CBQ), 
propranolol given 
until aggression 
stopped 
Sig. improvement compared to 
pre-treatment aggression levels 
(proxy rating); CMAI showed sig. 
reduction in physical and verbal 
aggression and wandering in 
responders (n =8) only. CBQ 
showed sig improvements in all 
subscales for resp. and non-resp. 
except wandering; lower MMSE 
correlated with treatment efficacy. 
No effect size reported. 
Wang & al. 
(2009) 
[27] 
How effective and 
tolerable is 
prazosin (alpha 
adrenergic blocker) 
for behavioural 
symptoms in AD 
patients? 
Double-blind 
RCT; duration 
8 wks 
Total n = 24 (n= 11 in 
treatment group; n=11 
in control group at 
baseline, n=7 in 
treatment group and n=6 
in placebo group at 
follow up) 
Clinical Global 
Impression of 
Change and change 
from baseline in NPI 
and BPRS; side 
effects, changes in 
BP, functional status 
Sig. improvement in all 
behavioural outcome measures in 
treatment group compared to 
placebo. Similar side effects, BP 
levels and functional status. No 
effect size reported. 
Weiler, 
Mungas & 
Bernick 
 Does propanolol 
(BB) improve 
disruptive 
6 case studies N=6 with dementia By-proxy 
observations  
Improvements in behaviour 
observed 
(1988) 
[29] 
behaviour?  
Depression Ban & al. 
(1990) 
[34] 
What effects has 
nimodipine (CCB) 
in dementia 
treatment? 
RCT N=178 with dementia, ; 
n=89 treatment (CCB); 
n=89 control  
depression Sig. more improvement regarding 
depression in treatment than 
placebo group. No effect size 
reported. 
Newman 
(1999) 
[35] 
What is the 
relationship of AD 
and VaD to 
depression? 
Cohort study n = 2341, n=749 AD; 
n=208 VaD; n=175 other 
dementia; of total  n = 
29 diagnosed with 
depression 
MMSE; cognitive and 
physical 
assessments, 
depression, BB use 
BB use was not a sig. covariate in 
the relationship between dementia 
and depression (OR not reported) 
Sleep 
problems, 
pain, kidney 
problems, 
incontinence 
Suzuki, 
Meguro & 
Meguro 
(2011) 
[39] 
Is there an 
association 
between sleep 
disturbance, 
decreased daily 
activity and 
impaired nocturnal 
reduction in BP in 
people with 
dementia? 
Prospective 
cohort study 
(14 days) 
N = 107 with dementia ADL, ABPM, 
evaluation of 
sleep/wake pattern 
No sig. differences in use of AHT 
between dippers and non-dippers 
or low and high ADL (no effect 
sizes reported) 
Ridgeway 
& al. 
(2008) 
[44] 
Which co-
morbidities and 
medicines are 
associated with 
urinary and fecal 
incontinence in a 
long-term care 
population? 
Retrospective 
cohort study 
N=67 female residents Medications, co-
morbidities 
Dementia was associated with 
urinary (OR 4.3, CI 1.3-17.4) and 
fecal (OR 6.8, CI 1.8 – 47.2) 
incontinence in a multivariate 
analysis. AHT was not associated 
with UI or FI (no effect sizes 
reported). 
Cholin-
esterase 
inhibitors 
Grossberg 
& al. 
(2000) 
[46] 
Are there any 
adverse pharmaco-
dynamic drug 
interactions with 
rivastigmine and 
other classes of 
medications?  
Prospective 
cohort study 
over 6 mnths 
N=2459; n=1696 using 
rivastigmine; n=763 
controls 
22 types of adverse 
events 
No significant pattern of increase 
in AEs was found for users of AHT 
as one group and beta blockers as 
well as alpha blockers as individual 
medication types. However, for 
diuretics, a significant difference 
was found between people with 
and without rivastigmine. 
Pariente & 
al. (2010) 
[47] 
What are factors 
associated with 
serious adverse 
Population 
study based 
on the French 
773 reports about 
cholinesterase inhibitors 
mentioning a total of 
ADRs leading to 
death, 
hospitalisation or 
Factors associated with serious 
ADRs were age, use of atypical 
antipsychotics, use of conventional 
drug reactions in 
patients treated 
with cholinesterase 
inhibitors? 
pharmaco-
vigilance 
database from  
drug 
launching up 
to 2007 
1044 ADRs prolongation of 
hospitalisation 
antipsychotics and use of AHT (OR 
2.11, CI 1.47-3.02); More patients 
with serious ADRs (33.8% of all 
patients)  than non-serious ADRs 
(19.7% of all patients) when using 
AHT alongside cholinesterase 
inhibitors. 
Rozzini & 
al. (2005) 
[45] 
What is the 
relationship 
between AHT and 
cholinesterase 
inhibitors?  
Prospective 
cohort study; 
40 wks 
N = 416; n=161 AHT 
users; n = 255 not AHT 
users 
MMSE, ADL,  Sig difference between AHT user 
and non-user in MMSE in favour of 
users at wk 16 (T2). No sig. 
difference at T3 (40wks). Sig. 
higher MMSE for users in those that 
respond to cholinesterase 
inhibitors, but not in non-
responders. No effect sizes 
reported.  
Tavassoli & 
al. (2007) 
[48] 
What are the drug 
interactions with 
cholinesterase 
inhibitors?  
Analysis of 
spontaneous 
reports 
regarding 
cholin-
esterase 
inhibitors 
N= 1058 spontaneous 
reports incl 
cholinesterase inhibitors 
Beta blockers, 
Calcium channel 
antagonists 
Beta blockers were among the 
most frequently encountered 
drugs involved in DDI (83 cases) 
with cholinesterase inhibitors 
Polypharmacy Giron & al. 
(2001) 
[50] 
What is the extent 
of inappropriate 
drug use in people 
with and without 
dementia? 
Prospective 
cohort study 
(8-10 yrs) 
N=681; n =188 with 
dementia; n = 493 
without dementia 
Drug groups; drug 
duplications 
People with dementia were sig. 
more likely to use high-ceiling 
diuretics and sig. less likely to use 
BBs and CCBs than people without 
dementia;  
no differences in drug duplication 
between people with and without 
dementia (no effect sizes 
reported). 
Montastruc 
& al. 
(2013) 
[51] 
What is the 
prevalence of 
potentially 
inappropriate 
medication use in 
people with mild to 
moderate AD? 
Prospective 
cohort study 
(4 yrs) 
N = 684 with AD ADL, MMSE, NPI, 
PIM use 
3.1% of sample used 
inappropriate centrally acting AHT; 
2.9% of sample used 
inappropriate short acting calcium 
channel inhibitors. 
Orthostatic Anderson & Is orthostatic Cross- AD n = 235; MMSE, medication, OH occurred sig. more in DLB than 
Hypotension al. (2008) 
[54] 
hypotension more 
common in people 
with dementia than 
in those without 
cognitive 
impairment? 
sectional 
cohort study 
DLB n = 52; controls n = 
62  
after resting in 
supine position: 
immediately and 
after 1,3,5,10 mins 
of standing 
in AD, and in AD sig. more than in 
controls.  
No sig. difference in AHT between 
groups. No effect sizes reported. 
Mehrabian 
& al. 
(2010) 
[55] 
What is the 
relationship 
between 
orthostatic 
hypotension (OH) 
and cognition in 
people with 
cognitive 
impairment?  
Cohort study Total total n = 495 
consecutive patients with 
memory complaints 
visiting a memory clinic 
Sitting and standing 
(after 1 and 3 min) 
BP. 
Patients with OH used a sig. 
higher number of AHT than those 
without OH. OH patients had sig. 
poorer cognitive function. This was 
independent of AHT. OH was 
significantly more often present in 
VaD, AD, MCI than in cognitively 
non-impaired individuals in an 
overall test (no individual 
differences or effect sizes 
reported).  
 
 
* CI refers to a 95% Confidence Interval; ABPM = ambulatory blood pressure monitoring; ACE-I = ACE inhibitor; AD = Alzheimer’s disease; ADL = activities of daily living; 
ADR = adverse drug reaction; AHT = antihypertensive treatment; ARB = angiotensin receptor blocker; BB = beta blockers; BP = blood pressure; BPRS = Brief Psychiatric 
Rating Scale; CAMCOG = Cambridge Cognition computerized cognitive test battery; CBQ = California Behavior Questionnaire; CDR = Clinical Dementia Rating; CCB = 
calcium channel blocker; CMAI = Cohen Mansfield Agitation Inventory; DDI = drug-drug interaction; DLB = dementia with Lewy bodies; FI = fecal incontinence; GFR = 
glomerular filtration rate; HR = hazard ratio; IRR = incidence rate ratio; MCI = mild cognitive impairment; MMSE = Mini Mental State Examination; mths = months; NPI = 
Neuropsychiatric Inventory; OH = orthostatic hypotension; OR = odds ratio; PDD = Parkinson’s disease dementia; PIM = potentially inappropriate medication; RCT = 
randomised controlled trial; SAE = serious adverse event; UI = urinary incontinence; VaD = vascular dementia; wks = weeks
 Discussion 
 
The first phase of this review identified several important domains of outcome relevant to the 
treatment of hypertension in people with dementia – not only cardio-vascular events but also falls, 
fractures and syncope, depression, orthostatic hypotension, behavioural disturbances, polypharmacy 
risks, kidney problems, incontinence, sleep problems, interactions with cholinesterase inhibitors and 
pain could also be affected. The second phase examined each of these areas in turn and concluded 
that relatively little is known about the effect of antihypertensive therapy upon these outcomes in 
people with dementia (as opposed to older people in general). From what we found, calcium channel 
blockers might have a beneficial additional effect upon depression, beta-blockers may reduce 
behaviour disturbance, ACE inhibitors might increase the risk of mortality, and there was no 
consistent evidence of any relationship between antihypertensive therapy and falls, orthostatic 
hypotension or interactions with cholinesterase inhibitors. Overall, relatively few studies of 
antihypertensive therapy have been undertaken in people with dementia, and there is virtually no 
information specific to different dementia sub-types. 
 
This review could be subject to a publication bias towards positive outcomes and benefits, and 
against the reporting of adverse consequences of treatment, which means that the possible benefits 
the review identified of antihypertensive treatment should be interpreted with caution. 
 
This review adds to the little that is known specifically about the treatment of hypertension in people 
with dementia. Previous reviews have proposed but not proven that such treatment might delay the 
onset of dementia
8-9
. Another review concluded that there is no convincing evidence of the 
effectiveness of antihypertensive therapy in the reduction of cardiovascular and cerebrovascular 
events in people with dementia
56
, which our review has confirmed. This review, however, illustrates 
the range of potential harms and benefits of antihypertensive therapy in people with dementia beyond 
those mentioned in most trials of antihypertensive agents – although it found little firm evidence about 
them. 
 
Given the lack of firm evidence of increased adverse outcomes arising from antihypertensive therapy 
in people with dementia, there is currently no reason to produce materially different guidelines for the 
treatment of hypertension in people with dementia, and justifies the current presumption that the 
favourable evidence drawn from the treatment of non-demented people should be extrapolated to 
those with dementia. As part of this guidance, the side effects of antihypertensive drugs should be 
sought on a routine basis: those looking after hypertension in people with dementia may need to 
gather a collateral history to do so adequately. Our review does not contradict guidance about 
prescribing in general in frailty states, which would apply to many people in the later stages of 
dementia: this includes withdrawing preventative medication in those believed to be in their last 
months of life when the potential benefits diminish in magnitude, and confirming whether the consent 
to treatment made by patients before the onset of dementia is still valid when they have lost mental 
capacity
57
. Our review also should not discourage physicians caring for acutely ill people with 
dementia from withdrawing antihypertensive drugs temporarily while they hare cardiovascular 
instability or are at high risk of problems such as acute kidney injury. 
      
Nevertheless, the lack of evidence of harm or benefit in this group means that there is at least a 
concern about the safety of antihypertensive treatment and a gap in the evidence base. Given the 
growing numbers of people with dementia and hence with dementia and hypertension, and growing 
concerns over both polypharmacy and frailty, we propose that clinicians should audit carefully their 
treatment of hypertension in this group of patients, trials of safe withdrawal of antihypertensive 
therapy should be considered for this population (as have been done for the general population)
58-59
 
taking the wide range of outcomes identified in this review into account, and more work is required to 
clarify the factors that should determine when antihypertensive therapy should be withdrawn in the 
later stages of the dementia process.  
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